Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neuroblastoma 16Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Osteosarcoma 1Neoplasms 1Neoplasm, Residual 1Leiomyosarcoma 1Ganglioneuroblastoma 1Bone Neoplasms 1

Interventions

Gemcitabine 7Doxorubicin 4Cyclophosphamide 4pembrolizumab 3Magnetic Resonance Spectroscopy 3Docetaxel 3Cisplatin 3regorafenib 2Vincristine 2Tranexamic Acid 2Sunitinib 2Standard of Care 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Radiation 2Proton Therapy 2Nivolumab 2Methotrexate 2Methods 2Interviews as Topic 2Indocyanine Green 2Everolimus 2Curettage 2Ascorbic Acid 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tocilizumab 1samarium Sm-153 lexidronam 1poly ICLC 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bone Neoplasms × dinutuximab × Clear all
NCT06669013 2024-11-01

FollowTheDIN

N.N. Petrov National Medical Research Center of Oncology

Phase 3 Recruiting
40 enrolled
Sarcoma

Bone Neoplasms, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡